Michael Ehrenstein

professor of rheumatology UCL

[Michael Ehrenstein @MikeEhrenstein]

Also present @cf_beesley

[Michael Ehrenstein @MikeEhrenstein]

Here are some of the team talking about our new clinical trial STRATIFY lupus ⁦@SLEuroSociety⁩ Lisbon ⁦@MuhammadShipa⁩

[Michael Ehrenstein @MikeEhrenstein]

Here are some of the team talking about our new clinical trial STRATIFY lupus ⁦@SLEuroSociety⁩ Lisbon ⁦@MuhammadShipa⁩

[Michael Ehrenstein @MikeEhrenstein]

Just out! We challenge the prevailing caution and advocate for a biomarker-guided approach soon to be tested in the STRATIFY lupus trial: Rituximab–belimumab combination for refractory SLE #lupus #PrecisionMedicine @MuhammadShipa @VersusArthritis
https://t.co/sP07zmYEmh

[John Reynolds @Dr_JohnR]

Are you a rheumatologist or nephrologist looking after patients with #lupus #nephritis in the UK?

We would like to invite you to take part in our research study to understand how treatment decisions are made.
https://t.co/4opHvblWmt

@lupusUK @UKKidney

[Michael Ehrenstein @MikeEhrenstein]

Validation and mechanistic insights for IgA2 as a companion biomarker of combination belimumab after rituximab for #lupus supporting the upcoming STRATIFY lupus trial https://t.co/vGOvP8Xgsa

[Md Yuzaiful Md Yusof @Yuz6Yusof]

A very productive 2-Day #BILAG #lupus meeting in Leeds to enhance recruitment of @NIHRresearch FIRST and @VersusArthritis @NIHRresearch @The_MRC STRATIFY-LUPUS - two trials opening in UK in 2026. Discussed Treat-to-Target & inspiring the next generation Lupus Leaders @LUPUSUK 🦋

[Michael Ehrenstein @MikeEhrenstein]

STRATIFY lupus: personalised care for patients | NIHR- a big thank you to all the lupus specialists and their patients who made this research possible as well as ⁦@VersusArthritis⁩ and ⁦@GSK⁩ https://t.co/DxEWOyE5GN

[muhammad shipa @MuhammadShipa]

📷🎉Exciting news!
Mike and I have been awarded a new grant to lead the STRATIFY Lupus—the FIRST EVER biomarker-enriched trial in lupus!
We’ll use biomarkers (IgA2 anti-DNA) to predict who responds best to treatment. @VersusArthritis, @NIHRresearch EME, @GSK , and @LUPUSUK

[The Lancet Rheumatology @TheLancetRheum]

NEW REVIEW—@LucyCarter6, @MikeEhrenstein & @edvital discuss the evolution and trajectory of B-cell targeted therapies in rheumatic diseases https://t.co/ptfLhlIPAR

[Michael Ehrenstein @MikeEhrenstein]

Research Fellow in immunology/rheumatology at UCL https://t.co/hvwsnzH2mp

[Michael Ehrenstein @MikeEhrenstein]

Exciting #researchopportunity to join our group to work on the #Immunology of #lupus working on biomarkers and mechanisms of response to B cell targeted therapies with @MuhammadShipa @louisakjames https://t.co/SPAyPo5CFp

[Michael Ehrenstein @MikeEhrenstein]

And a big shout out to @MuhammadShipa who has helped to make the STRATIFY lupus trial possible and will be joining @DoM_UCL as a Principal Research Fellow and consultant rheumatologist.

[Michael Ehrenstein @MikeEhrenstein]

Thanks to @VersusArthritis and NIHR who have just agreed to jointly provide £1.7M to support a precision medicine trial in #lupus. Thanks to @GSK for providing free belimumab, and to all the UK lupus experts for agreeing to help recruit patients. #WorldLupusDay @NIHR_Industry

[Michael Ehrenstein @MikeEhrenstein]

Hope to start recruiting to the STRATIFY lupus trial in early 2025

[Michael Ehrenstein @MikeEhrenstein]

Important research from @Dr_JohnR and colleagues highlighting the differences in management approaches for #lupus nephritis within the UK and that rituximab remains the most popular choice for refractory renal disease https://t.co/vcxziBuN7j

[Nature Medicine @NatureMedicine]

Academic clinician–scientists risk becoming an endangered species.

World View from @StephenORahilly @Cambridge_Uni

https://t.co/J5tnEYlvOQ

[Michael Ehrenstein @MikeEhrenstein]

Very proud of @MuhammadShipa who successfully defended his thesis this afternoon. Well done! Thanks to @VersusArthritis and @LUPUSUK for supporting his research.

[Journal of Experimental Medicine @JExpMed]

Clinical trials provide a unique substrate to understand pathogenesis and identify biomarkers to targeted therapies in #SLE which can be used to stratify patients. Taken from a new Viewpoint by @MikeEhrenstein ⁦and ⁦⁦@MuhammadShipa⁩: https://t.co/JcwXz7qTsQ

[Michael Ehrenstein @MikeEhrenstein]

Well done ⁦@MuhammadShipa⁩ for the nomination from Department of Inflammation for the ⁦@DoM_UCL⁩ research award. Good luck! https://t.co/d3JYyTwENa